Skip to main content

A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma

Publication ,  Journal Article
Chandramohan, V; Bigner, DD
Published in: OncoImmunology
December 1, 2013

Both the amplification of the gene coding for wild-type (wt) epidermal growth factor receptor (EGFR) and the overexpression of the EGFR deletion mutant, commonly known as EGFRvIII, are hallmarks of glioblastoma. We have recently reported a novel, recombinant immunotoxin, D2C7-(scdsFv)-PE38KDEL, that targets both wt EGFR and EGFRvIII, exhibiting potent antineoplastic effects against established murine gliomas. © 2013 Landes Bioscience.

Duke Scholars

Published In

OncoImmunology

DOI

EISSN

2162-402X

ISSN

2162-4011

Publication Date

December 1, 2013

Volume

2

Issue

12

Start / End Page

1 / 2

Related Subject Headings

  • 1112 Oncology and Carcinogenesis
  • 1107 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chandramohan, V., & Bigner, D. D. (2013). A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma. OncoImmunology, 2(12), 1–2. https://doi.org/10.4161/onci.26852
Chandramohan, V., and D. D. Bigner. “A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma.” OncoImmunology 2, no. 12 (December 1, 2013): 1–2. https://doi.org/10.4161/onci.26852.
Chandramohan, V., and D. D. Bigner. “A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma.” OncoImmunology, vol. 2, no. 12, Dec. 2013, pp. 1–2. Scopus, doi:10.4161/onci.26852.

Published In

OncoImmunology

DOI

EISSN

2162-402X

ISSN

2162-4011

Publication Date

December 1, 2013

Volume

2

Issue

12

Start / End Page

1 / 2

Related Subject Headings

  • 1112 Oncology and Carcinogenesis
  • 1107 Immunology